APA (7th ed.) Citation

K, G., K, P., JA, W., FL, A., G, B., L, J., . . . R, S. (2026). Feasibility and acceptability of daily oral emtricitabine/tenofovir alafenamide fumarate (FTC/TAF) for HIV pre-exposure prophylaxis among people who inject drugs with opioid use disorder. Sexually transmitted infections. https://doi.org/10.1136/sextrans-2025-056770

Chicago Style (17th ed.) Citation

K, Gautam, et al. "Feasibility and Acceptability of Daily Oral Emtricitabine/tenofovir Alafenamide Fumarate (FTC/TAF) for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs with Opioid Use Disorder." Sexually Transmitted Infections 2026. https://doi.org/10.1136/sextrans-2025-056770.

MLA (9th ed.) Citation

K, Gautam, et al. "Feasibility and Acceptability of Daily Oral Emtricitabine/tenofovir Alafenamide Fumarate (FTC/TAF) for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs with Opioid Use Disorder." Sexually Transmitted Infections, 2026, https://doi.org/10.1136/sextrans-2025-056770.